Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Bassanelli M, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Montironi R, Battelli N, Porta C. Santoni M, et al. Among authors: battelli n. Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27. Target Oncol. 2023. PMID: 37369815
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
Sanna G, Fabi A, Crivellari D, Saracchini S, Battelli N, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L. Sanna G, et al. Among authors: battelli n. Tumori. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904. Tumori. 2014. PMID: 25296593
[Biologic aspects and clinical use of granulocyte growth factor].
Rupoli S, Battelli N, Del Prete S, Salvi A, Cinciripini A, Scortechini AR, Cantori I, Barulli S, Leoni P. Rupoli S, et al. Among authors: battelli n. Recenti Prog Med. 1995 Dec;86(12):510-7. Recenti Prog Med. 1995. PMID: 8588087 Review. Italian.
Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Massari F, et al. Among authors: battelli n. Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Cancer Treat Rev. 2018. PMID: 29407369 Review.
Durvalumab in Stage III Non-Small-Cell Lung Cancer.
Santoni M, Battelli N, Buti S. Santoni M, et al. Among authors: battelli n. N Engl J Med. 2018 Mar 1;378(9):869. doi: 10.1056/NEJMc1716426. N Engl J Med. 2018. PMID: 29504721 No abstract available.
Tivozanib for the treatment of renal cell carcinoma.
Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Santoni M, et al. Among authors: battelli n. Expert Opin Pharmacother. 2018 Jun;19(9):1021-1025. doi: 10.1080/14656566.2018.1480722. Epub 2018 May 31. Expert Opin Pharmacother. 2018. PMID: 29851529
108 results